IPP Bureau

CARsgen Therapeutics opens new U.S. cGMP facility for CAR T production
CARsgen Therapeutics opens new U.S. cGMP facility for CAR T production

By IPP Bureau - February 22, 2022

The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe

Abbott's CardioMEMS HF System receives USFDA approval
Abbott's CardioMEMS HF System receives USFDA approval

By IPP Bureau - February 22, 2022

New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure

Prestige BioPharma’s facility receives EU-GMP certification
Prestige BioPharma’s facility receives EU-GMP certification

By IPP Bureau - February 22, 2022

The facility will manufacture its Herceptin biosimilar, Tuznue

AIIA launches ‘Ayush Start-up Challenge’
AIIA launches ‘Ayush Start-up Challenge’

By IPP Bureau - February 22, 2022

AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector

AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers
AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers

By IPP Bureau - February 22, 2022

New inhalers would have near-zero Global Warming Potential propellant

Mental healthcare app heyy raises pre-seed funding
Mental healthcare app heyy raises pre-seed funding

By IPP Bureau - February 22, 2022

US $ 555,000 invested by Wavemaker Partners in pre-seed round

Velocity Clinical Research invests in Indian tech, acquires TrierHealth
Velocity Clinical Research invests in Indian tech, acquires TrierHealth

By IPP Bureau - February 22, 2022

The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials

UK MHRA approves Marksans  All in One oral solution
UK MHRA approves Marksans All in One oral solution

By IPP Bureau - February 22, 2022

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs

Asahi Kasei to build new production unit for membrane virus filters in Japan
Asahi Kasei to build new production unit for membrane virus filters in Japan

By IPP Bureau - February 22, 2022

The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market

Solvay invests in Zurich-based 3D printing startup
Solvay invests in Zurich-based 3D printing startup

By IPP Bureau - February 22, 2022

9T Labs provides a cost-competitive solution for manufacturing that will allow structural CFRP parts to replace metals at a much faster rate in demanding applications in many sectors such as aerospace, automotive and healthcare

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma

By IPP Bureau - February 22, 2022

The transaction as well as the open offer is expected to be completed by June this year.

IFF to acquire contract manufacturer of dietary supplements Health Wright Products
IFF to acquire contract manufacturer of dietary supplements Health Wright Products

By IPP Bureau - February 22, 2022

The sale is expected to close in the first quarter of 2022

Dow, Sartorius and Südpack collaborate to support global supply of coronavirus vaccines
Dow, Sartorius and Südpack collaborate to support global supply of coronavirus vaccines

By IPP Bureau - February 22, 2022

Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply

CanSinoBIO's Convidecia approved as heterologous booster in China
CanSinoBIO's Convidecia approved as heterologous booster in China

By IPP Bureau - February 21, 2022

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants

Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s
Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s

By IPP Bureau - February 21, 2022

Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company

Latest Stories

Interviews

Packaging